Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers

  1. Bruce D. Walker1,2,3,*
  1. 1Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts
  2. 2Harvard University Center for AIDS Research, Boston, Massachusetts
  3. 3Howard Hughes Medical Institute, Chevy Chase, Maryland
  4. 4Division of Infectious Diseases, Advanced Clinical Research Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan
  5. 5Simon Fraser University, Burnaby, BC, Canada
  6. 6BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
  7. 7Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, California
  8. 8University of Colorado Denver, Division of Infectious Diseases, Aurora, Colorado
  9. 9Jessen-Praxis, Berlin, Germany
  10. 10National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, NSW, Australia
  11. 11Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York
  12. 12Department of Medicine, University of California at San Diego, San Diego, California
  13. 13Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California at San Diego, San Diego, California

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) controllers maintain viremia at <2,000 RNA copies/ml without antiretroviral therapy. Viruses from controllers with chronic infection were shown to exhibit impaired replication capacities, in part associated with escape mutations from cytotoxic-T-lymphocyte (CTL) responses. In contrast, little is known about viruses during acute/early infection in individuals who subsequently become HIV controllers. Here, we examine the viral replication capacities, HLA types, and virus sequences from 18 HIV-1 controllers identified during primary infection. gag-protease chimeric viruses constructed using the earliest postinfection samples displayed significantly lower replication capacities than isolates from persons who failed to control viremia (P = 0.0003). Protective HLA class I alleles were not enriched in these early HIV controllers, but viral sequencing revealed a significantly higher prevalence of drug resistance mutations associated with impaired viral fitness in controllers than in noncontrollers (6/15 [40.0%] versus 10/80 [12.5%], P = 0.018). Moreover, of two HLA-B57-positive (B57+) controllers identified, both harbored, at the earliest time point tested, signature escape mutations within Gag that likewise impair viral replication capacity. Only five controllers did not express “protective” alleles or harbor viruses with drug resistance mutations; intriguingly, two of them displayed typical B57 signature mutations (T242N), suggesting the acquisition of attenuated viruses from B57+ donors. These data indicate that acute/early stage viruses from persons who become controllers have evidence of reduced replication capacity during the initial stages of infection which is likely associated with transmitted or acquired CTL escape mutations or transmitted drug resistance mutations. These data suggest that viral dynamics during acute infection have a major impact on HIV disease outcome.

FOOTNOTES

    • Received 6 February 2010.
    • Accepted 12 May 2010.
  • *Corresponding author. Mailing address for Bruce D. Walker: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, 149 13th St., Room 5212, Charlestown, MA 02129. Phone: (617) 724-8332. Fax: (617) 726-4691. E-mail: bwalker{at}partners.org. Mailing address for Toshiyuki Miura: Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5338. Fax: 81-5449-5427. E-mail: miura523{at}ims.u-tokyo.ac.jp
  • § These authors contributed equally.

  • Published ahead of print on 26 May 2010.

| Table of Contents